focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,086.00
Bid: 13,892.00
Ask: 11,282.00
Change: -80.00 (-0.66%)
Spread: -2,610.00 (-18.788%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Europe recasts COVID-19 vaccine playbook after first-round flop

Thu, 01st Apr 2021 18:37

* For a graphic on vaccine roll-out, see: https://tmsnrt.rs/3fzstuP

By John Miller and Ludwig Burger

ZURICH, April 1 (Reuters) - Europe, under fire for fumbling
its vaccine roll-out and fighting a fresh wave of infections, is
scrambling to speed up the pace of injections and avoid being
left further behind by Britain and the United States.

In Paris, the city's hallowed national soccer stadium is
being transformed into a mass vaccination hub, while Italy -
with 20,000 infections daily - has put the army and civil
defence agency in charge, after new Prime Minister Mario Draghi
fired the country's vaccine czar.

Over Easter, Germany's North Rhine-Westphalia state is
relaxing rules on who can get 450,000 doses of AstraZeneca's
vaccine. Clotting concerns have prompted the country to
limit the vaccine to people over the age of 60, but North
Rhine-Westphalia hopes its measures will now allow more people
in that age group to get a first dose.

Originally, it had wanted to give the AstraZeneca vaccine to
pregnant women and their partners, among other priority groups.

"We can't do that anymore, because I assume that those
people ... are under 60," North Rhine Westphalia's Health
Minister Karl-Josef Laumann told reporters.

"We didn't want to bunker these shots, we decided we would
get them via vaccination centres to people as quickly as
possible."

Europe's urgency to reverse what the World Health
Organization branded on Thursday an "unacceptably slow" start to
vaccinations is growing, as variants first detected in Britain,
South Africa and now Brazil whip up angst that acting too slowly
will let the virus proliferate again.

The chaos of Europe's roll-out has been exacerbated by
squabbling over vaccine exports, health concerns over
AstraZeneca's vaccine and some temporary delivery delays
affecting Pfizer, Moderna and AstraZeneca
vaccines.

The European Union was slower than Britain and the United
States, not only to order vaccines last year from companies but
also in approving them. Even once they were approved,
vaccination rates have been disappointing.

The WHO estimates just 4% of 750 million people in 53
countries across continental Europe, from wealthier Scandinavia
to poorer Balkan countries, have been fully vaccinated, a
quarter of the U.S. count.

While the European Union's vaccination rate is slowly
climbing, only 13.4% of adults in the bloc have had at least one
shot, according to Europe's vaccine tracker.

By contrast, more than half of adult Britons and 38% of U.S.
adults have received at least one dose, official figures and
Reuters calculations show.

Still, the situation is improving: A Reuters analysis shows
the seven-day average for the four largest countries - Germany,
France, Italy and Spain - was at its highest yet during the last
week.

Since Spain resumed AstraZeneca shots on March 24 after
suspending them temporarily over clotting concerns, its
seven-day rolling average of vaccinations rose to nearly 200,000
shots a day, from 95,283 daily a week earlier, Spanish officials
said.

The country is now converting venues like conference centres
and, like France, football stadiums, into mass vaccination
centres, and expects to inoculate 70% of its 47 million
population by the end of summer.

Spanish Health Minister Carolina Darias has said that April
will be "an inflection point", as more vaccines flood into the
country.

The EU expects a major ramp-up of deliveries in the second
quarter will be sufficient to inoculate at least 255 million
people, or 70% of its adult population, by July.

About 200 million doses of Pfizer-BioNTech's vaccine are due
in the quarter, enough for 100 million people, while deliveries
of Johnson & Johnson's single-dose shot will start this
month.

VETS, DENTISTS, COMPANIES

France is also converting veterinarian and dentists' offices
into vaccine centres, while Italy has abandoned primrose-shaped
pavilions in its squares and is getting doctors, dentists and
pharmacists to dispense doses instead. The aim is to more than
double daily vaccinations to half a million from 230,000
currently.

Pharmacies in Switzerland are also preparing to start
offering doses to people over 65 this month, but the government
expects that once mass vaccinations become possible, likely
sometime in May, private companies will have a role, similar to
flu clinics some offer each year to employees.

The Swiss government expects 10.5 million doses by July,
enough for roughly 5.2 million people.

"There won't just be shots in vaccination centres, doctors
and pharmacists," Swiss Health Minister Alain Berset said on
Wednesday. "That's something we're hoping for, something we're
supporting."

(Reporting by John Miller in Zurich, Ludwig Burger in
Frankfurt, Emilio Parodi in Milan, Francesco Guarascio in
Brussels, Matthias Blamont in Paris, Maria Sheahan in Berlin,
Nathan Allen in Madrid;
Editing by Josephine Mason and Susan Fenton)

More News
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.